SigOnco to Spotlight AI-Driven Organoid Platform at the 15th Healthy China Forum

Tomorrow afternoon,Dr. Zhuo Shu, Vice President of R&D at Signet Therapeutics, has been invited to attend the "15th Healthy China Forum" meticulously planned by the People's Health Client of the People's Daily.Dr. Zhuo Shu will deliver a speech titled "Organoid Disease Models Integrated with AI Empower Innovation in Targeted Cancer Drug Development" at the parallel forum "Digital Technology Leading the Way to Healthy China" hosted by Vascular Network, and participate in the subsequent roundtable discussion.。

This forum closely aligns with the strategic direction of the "Three-Year Action Plan for Improving National Health Literacy (2024-2027)" issued by the National Health Commission, aiming to drive a profound transformation in China's health care sector from "treatment-focused" to "health promotion." Dr. Zhuo Shu from Signet Therapeutics willA Deep Dive into How the Powerful Combination of Cutting-Edge Organoid Disease Models and AI Technology Paves Innovative Pathways and Solutions for Targeted Drug Development in Cancer Treatment。

During the forum, top experts from the pharmaceutical industry, healthcare policy, medical investment, and other fields will gather together, including presidents of renowned tertiary hospitals in China, chairpersons of various professional branches of the Chinese Medical Association, presidents of various branches of the Chinese Medical Doctor Association, as well as mainstream media outlets in China, jointly building a high-level, in-depth exchange platform. SIGNET will seize this valuable opportunity to comprehensively showcase its core advantages in the field of innovative oncology drug development, highlighting its use of cutting-edge organoid disease models combined with AI technology.It took only more than three years to push the world's first targeted drug for diffuse gastric cancer to Phase I clinical stage (SIGX1094).Dr. Zhuo Shu will also engage in in-depth exchanges with industry peers during the roundtable discussion, jointly promoting the vigorous development of the digital healthcare industry.

Meeting NameThe 15th Healthy China Forum

Sharing Time: September 19, 2024, 14:00-16:40

Organizer: People's Daily Health Client

Conference Location: Beijing · China World Hotel, First Floor Conference Hall

Signet Therapeutics is the first company in China to develop innovative targeted cancer drugs based on organoid disease models and AI. Initially founded on the Harvard University campus, it was established in Shenzhen in 2020 and completed an angel round of financing amounting to nearly 150 million yuan within a year. Signet is not only a phonetic translation of "Signet," but also adheres to the vision of "Hopeful Minds, Investigating Things to Attain Knowledge." The company leverages the crucial role of organoid disease models that closely resemble patient genomic characteristics in efficacy evaluation and new target discovery, combined with AI-powered screening, synthesis, and optimization of small molecule compounds, to develop first-in-class innovative targeted drugs. Currently, the company has three drug pipelines, with the lead pipeline developing the world’s first targeted drug for diffuse gastric cancer, which has now entered Phase I clinical trials. The company has a 1,200-square-meter R&D facility and a 500-square-meter experimental animal housing area. Signet Therapeutics' disease model platform not only serves its own drug pipelines but also actively empowers large pharmaceutical companies in new drug development, contributing to the creation of more innovative drugs.